Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

The common objective of developing and applying bioinformatics tools to better understand cancer biology fosters close interaction between the groups inside the Division of Applied Bioinformatics and cooperation with the Computational Oncology group in the Division of Theoretical Bioinformatics.

Comparative Cancer Genomics

The Comparative Cancer Genomics team lead by Dr. Lars Feuerbach focuses on integrating sequencing and array data across tumor subtypes and patient cohorts. In these Pan-Cancer studies the similarities and differences in the interplay of epigenome, genome and transcriptome during carciogenesis are investigated in context of three main interests:

Focus 1 - Replicative Immortality and telomere biology in cancer

Focus 2 - Identification of regulatory cancer driver mutations for precision oncology applications

Focus 3 - Software tool development for the analysis of cancer cohorts

Furthermore, following up on the ICGC Early-onset Prostate Cancer consortium, we study prostate cancer as part of the Pan Prostate Cancer group of the ICGC ARGO project.

Our methodological expertise for computational cancer genome analysis comprises algorithm development, specialized datastructures for multi-omics data integration, data mining by machine learning, compact visualization of complex information, and statistical modeling.

Computational Oncoimmunology

The Computational Oncoimmunology team lead by Dr. Charles Imbusch focuses on questions regarding the immune system in general and more specifically under pathogenic conditions such as cancer. To address these questions NGS, as well as array technologies, are routinely utilized.

With the advent of multiple single cell technologies it is now possible to differentiate subpopulations captured in an assay, allowing to address cell heterogeneity and the discovery of rare cell populations. We focus on the downstream analysis of scRNA-seq and scTCR to robustly identify and describe cell populations, study dynamic cross-talk between tumor and immune cells while keeping up to date with most recent algorithmic developments.

Alternatively to single cell assays we apply and develop methods to deconvolute from bulk data cell types, integrating epigenetic and transcriptomic data to describe the tumor microenvironment.

Tumor Heterogeneity and Evolution

The Tumor Heterogeneity and Evolution team lead by Dr. Sadaf Mughal focuses on the application of computational methods to analyze omics data from patient cohorts to understand cancer heterogeneity, tumor evolution and to decipher the immune crosstalk in cancer progression and metastatic spread. We are particularly interested in learning drug resistance mechanisms tumor employ during evolution. For this we are investigating longitudinal samples to predict the evolutionary trajectories of aggressive metastatic subclones. Furthermore, we are studying the tumor-immune coevolution to address inter- and intra-tumoural heterogeneity, dictating progression of disease.

to top
powered by webEdition CMS